Core Insights - The article highlights the growth and strategic direction of New芝生物, emphasizing its transformation into a comprehensive service provider in the life sciences instrument sector since its listing on the Beijing Stock Exchange in 2022 [1][2][6] Company Overview - New芝生物 is one of the early companies in China focusing on the research, production, and sales of life science instruments, currently offering over 200 product models across more than 20 product lines [2] - The company has expanded its product offerings to cover the entire process from experimentation to pilot testing and mass production, moving beyond traditional laboratory equipment [2] Product Development and Innovation - The company continues to iterate on traditional products while expanding new product lines, including industrial-grade applications in ultrasonic processing and customized solutions for various industries [2][3] - New芝生物 has achieved significant technological breakthroughs, allowing it to develop products that meet international standards, such as anaerobic microbial growth curve analyzers [4] Strategic Acquisitions - Following its listing, New芝生物 has accelerated industry consolidation through capital means, exemplified by its acquisition of a 55% stake in 宁波阿弗斯恒温公司 to enhance its industrial temperature control solutions [3] Market Positioning and Global Strategy - The company is shifting its strategic focus towards high-end instruments and global expansion, leveraging the current emphasis on domestic production and technological self-sufficiency [4] - New芝生物 plans to establish a localized service network for its overseas operations, moving from reliance on foreign distributors to a direct service model [5] Capital Market Impact - The establishment of the Beijing Stock Exchange has provided a platform for innovative SMEs like New芝生物 to access capital, enhance brand influence, and attract talent [6] - The company aims to become a "research supermarket" and a provider of comprehensive solutions, benefiting from collaboration opportunities with leading firms in niche markets [6]

Core Insights - New Zhi Bio, the first stock in life science instruments listed on the Beijing Stock Exchange, emphasizes the importance of innovation and capital support for small and medium-sized enterprises [2][3] Company Overview - New Zhi Bio is one of the earliest companies in China focused on the research, production, and sales of life science instruments, with over 20 product lines and more than 200 product models [3] - The company has transitioned from a laboratory equipment supplier to a comprehensive service provider covering the entire process from experimentation to mass production [3][4] Product Development - The company continues to innovate in traditional product lines while expanding new product lines, including customized models for various industries, maintaining a stable customized business ratio of over 20% [3][4] - New Zhi Bio has achieved significant technological breakthroughs in ultrasonic processing and freeze-drying, enabling the development of industrial-grade products [3] Strategic Expansion - The company is focusing on integrating capital to accelerate industrial consolidation, exemplified by the acquisition of a 55% stake in Ningbo Afus Constant Temperature Company to enhance its industrial temperature control solutions [4] - New Zhi Bio is shifting its strategic focus towards high-end instruments and global expansion, leveraging the increasing emphasis on independent control of scientific instruments at the national level [5][6] Market Positioning - The company has reached a critical stage in achieving independent control over life science instruments, with some products nearing or surpassing international advanced levels [6] - New Zhi Bio plans to establish a localized service network for its overseas markets, moving from reliance on foreign distributors to a direct service model [6] Capital Market Insights - The Beijing Stock Exchange has played a crucial role in supporting innovative small and medium-sized enterprises, fostering a development pattern that balances quantity and quality [7] - The listing has enhanced the company's brand influence, talent attraction, and shareholder structure, allowing it to compete effectively in the talent market [7] - New Zhi Bio aims to become a "research supermarket" and a provider of comprehensive solutions, leveraging opportunities for collaboration with leading companies in niche markets [7]

Core Viewpoint - New Zhi Bio, the first stock in life science instruments listed on the Beijing Stock Exchange, emphasizes the importance of innovation and capital support for small and medium-sized enterprises, enhancing brand influence and overall capabilities in product development and market expansion [1][6]. Company Overview - New Zhi Bio is one of the earliest companies in China focused on the research, production, and sales of life science instruments, with over 20 product lines and more than 200 product models covering three main areas: biological sample processing, molecular biology and drug research, and laboratory automation [2]. - The company has transitioned from a laboratory equipment supplier to a comprehensive service provider covering the entire process from experimentation to mass production [2]. Product Development and Market Strategy - The company continues to iterate on traditional products while expanding new product lines, with a focus on customer feedback to drive product matrix enrichment [2]. - New Zhi Bio has developed specialized models for cross-industry applications, maintaining a customized business ratio of over 20% [2]. Strategic Direction and Acquisitions - The company is leveraging capital to accelerate industry integration, exemplified by the acquisition of 55% of Ningbo Afus Constant Temperature Company to enhance its industrial temperature control solutions [3]. - The acquisition aligns with New Zhi Bio's existing channels and brand advantages, providing new growth opportunities [3]. Global Expansion and Localization - New Zhi Bio is shifting its strategic focus towards high-end instruments and global layout, with an emphasis on self-sufficiency in scientific instruments [4]. - The company plans to establish a localized service network abroad, moving from reliance on foreign distributors to a "sales-application-after-sales" service model [5]. Capital Market Insights - The Beijing Stock Exchange has played a crucial role in supporting innovative SMEs, fostering a development pattern that balances quantity and quality [6]. - The listing has not only provided financial support but also enhanced talent attraction, optimized shareholder structure, and increased brand influence [6]. - New Zhi Bio aims to become a "research supermarket" and a provider of comprehensive solutions, leveraging opportunities for collaboration with leading companies in niche markets [6].

证券代码：430685 证券简称：新芝生物 公告编号：2025-095 宁波新芝生物科技股份有限公司 关于分公司开立募集资金专户并签署募集资金四方监管协议的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 三、募集资金四方监管协议的签署情况 根据《北京证券交易所股票上市规则》《北京证券交易所上市公司持续监管 指引第 9 号——募集资金管理》《募集资金管理制度》等相关规定及要求，杭州 分公司开立了募集资金专项账户，并与本公司、保荐机构中信证券股份有限公司、 上海浦东发展银行股份有限公司宁波高新区支行于 2025 年 9 月 28 日签署了《募 集资金四方监管协议》。 四、本次分公司开立募集资金专户信息 账户名称：宁波新芝生物科技股份有限公司研发与创新杭州分公司募集资金 专户 开户银行：上海浦东发展银行股份有限公司宁波高新区支行 账号：94130078801800003607 募集资金专户用途：研发中心建设项目 一、募集资金基本情况 经中国证券监督管理委员会于 2022 年 9 月 2 日证监许可〔20 ...

证券代码：430685 证券简称：新芝生物 公告编号：2025-096 宁波新芝生物科技股份有限公司 关于完成注销全资子公司的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 一、注销情况 宁波新芝生物科技股份有限公司（以下简称"公司"）于2025年6月23日召开第 八届董事会第二十次会议，审议通过了《关于拟注销全资子公司的议案》。全资子公 司新芝科技（杭州）有限公司（以下简称"新芝杭州"）未实际开展经营，基于公司 整体经营规划的考虑，为了更好的整合公司资源，提高公司运营效率，公司董事会同 意注销全资子公司新芝杭州。 近日，新芝杭州的注销手续已经全部办理完毕。 二、注销全资子公司的基本情况 1、名称：新芝科技（杭州）有限公司 统一社会信用代码：91330108MA2HXY6T4T 类型：有限责任公司（自然人投资或控股的法人独资） 法定代表人：周芳 注册资本：500万元 成立日期：2020年6月2日 项目：第三类医疗器械经营(依法须经批准的项目，经相关部门批准后方可开展经营 活动，具体经营项目以审批结 ...

关于宁波新芝生物科技股份有限公司 中信证券股份有限公司 二、发现的问题及采取的措施 2025年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》等有关 法律法规、规范性文件等的规定,中信证券股份有限公司(简称"中信证券")作为宁 波新芝生物科技股份有限公司的保荐人,负责宁波新芝生物科技股份有限公司公司的持 续督导工作,并出具 2025半年度持续督导跟踪报告。 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | | 保荐人查阅了公司信息披露文件,信息披 | 不适用 | | | 露管理制度,内幕信息管理和知情人登记 | | | 1. 信息披露 | 管理情况,会计师出具的2024年度内部控 | | | | 制鉴证报告,检索公司舆情报道、对公司 | | | | 高级管理人员进行访谈等,未发现公司在 | | | | 信息披露方面存在重大问题。 | | | | 保荐人查阅了公司章程及内部制度文件, | 针对宁波局指出的待整改问题,保荐人采 取了以下措施: | | | 查阅了公司2024年度内部控制自我评价报 | (1) 督导上市公司选聘内部审计 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company reported a revenue of 71 million yuan for the first half of 2025, reflecting a year-on-year increase of 6.4%, while net profit decreased by 9.1% to 12 million yuan [1] - The revenue and profit figures for the first half of 2025 fell short of expectations, prompting a downward revision of profit forecasts for 2025-2027 [1][7] - The company is expected to benefit from a recovery in downstream demand starting in 2025, with a clear product strategy focused on life science instruments [7] Financial Data and Profit Forecast - Total revenue projections for 2025-2027 are revised to 187 million, 215 million, and 249 million yuan respectively, with corresponding net profit estimates of 47 million, 52 million, and 61 million yuan [1][7] - The company's gross margin for the first half of 2025 was 62.5%, a slight increase from the previous year, while net margin decreased marginally to 12.5% [7] - The company’s earnings per share are projected to be 0.51 yuan for 2025, increasing to 0.67 yuan by 2027 [1][7]

Investment Rating - The investment rating for the company is "Outperform" (Maintain) [3] Core Views - The company reported a revenue of 71.15 million yuan for H1 2025, representing a year-on-year increase of 6.39%, while the net profit attributable to the parent company was 11.87 million yuan, down 9.15% year-on-year. The net profit after deducting non-recurring gains and losses increased by 4.76% year-on-year [5] - The company maintains its profit forecast for 2025-2027, expecting net profits of 44 million yuan, 50 million yuan, and 55 million yuan respectively, with corresponding EPS of 0.48 yuan, 0.54 yuan, and 0.61 yuan per share, leading to PE ratios of 35.4, 31.6, and 28.3 times respectively [5] Financial Performance Summary - As of June 30, 2025, the company had a total of 87 authorized patents, including 21 invention patents. In H1 2025, revenue from biological sample processing, laboratory automation and general equipment, and molecular biology and drug research products was 41.66 million yuan, 17.39 million yuan, and 5.70 million yuan respectively, with year-on-year growth rates of 7.27%, 5.51%, and 1.29% [6] - The company is positioned in a market where over 80% of large analytical instruments are imported, indicating significant domestic market potential. The global analytical instrument market is projected to reach 60 billion USD by 2025, with a CAGR of 6.5% expected until 2034 [7] Financial Forecasts - The company's projected financials for 2023A to 2027E include: - Revenue: 191 million yuan (2023A), 168 million yuan (2024A), 173 million yuan (2025E), 195 million yuan (2026E), 218 million yuan (2027E) [11] - Net profit: 58 million yuan (2023A), 42 million yuan (2024A), 44 million yuan (2025E), 50 million yuan (2026E), 55 million yuan (2027E) [11] - EPS: 0.64 yuan (2023A), 0.45 yuan (2024A), 0.48 yuan (2025E), 0.54 yuan (2026E), 0.61 yuan (2027E) [12]

Group 1 - The company announced that its first extraordinary general meeting of shareholders for 2025 will be held on August 29, 2025 [2] - The meeting will review and approve multiple proposals, including the "Proposal on the Formulation and Revision of Certain Corporate Governance Systems" [2]

宁波新芝生物科技股份有限公司 章程 二○二五年八月 | 第一章 总则 | | --- | | 第二章 经营宗旨和范围 | | 第三章 股份 . | | 第一节 股份发行 . | | 第二节 股份增减和回购 | | 第三节 股份转让 ………………………………………………………………………………………………………………………… 5 | | 第四章 股东和股东会 | | 第一节 股东的一般规定 . | | 第二节 控股股东和实际控制人 . | | 第三节 股东会的一般规定 | | 第四节 股东会的召集 . | | 第五节 股东会的提案与通知 | | 第六节 股东会的召开 . | | 第七节 股东会的表决和决议 | | 第五章 董事和董事会 | | 第一节 董事的一般规定 | | 第二节 董事会 …………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 27 | | 第三节 独立董事 | | 第四节 董事会专门委员会 - | | 第六章 高级管理人员 . | | 第七 ...